Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
- 23 July 2013
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 98 (3), 337-345
- https://doi.org/10.1007/s12185-013-1402-0
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Multiple MyelomaThe New England Journal of Medicine, 2011
- A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding StudyClinical Cancer Research, 2010
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood, 2010
- Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myelomaBone Marrow Transplantation, 2010
- Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyHaematologica, 2010
- Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myelomaThe Korean Journal of Hematology, 2010
- Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple MyelomaCancer Research, 2009
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaThe New England Journal of Medicine, 2008
- Comparison of high‐dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myelomaCancer, 2004